APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antifibrotic Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antifibrotic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025191 pages

Choose your research edition.

Industry ResearchAntifibrotic Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Antifibrotic Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Antifibrotic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antifibrotic Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Antifibrotic Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Antifibrotic Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antifibrotic Drug include Accord Healthcare, Amneal Pharmaceuticals, Apotex, Beacon Pharma, Boehringer Ingelheim, Eskayef Pharmaceuticals, ScieGen Pharmaceuticals, Gyre Pharmaceuticals and Kawin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antifibrotic Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antifibrotic Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antifibrotic Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antifibrotic Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Antifibrotic Drug Segment by Company

Accord Healthcare

Amneal Pharmaceuticals

Apotex

Beacon Pharma

Boehringer Ingelheim

Eskayef Pharmaceuticals

ScieGen Pharmaceuticals

Gyre Pharmaceuticals

Kawin

Roche

Qilu Pharmaceutical

PuraCap

Sandoz

CSPC Pharmaceutical Group

Kelun Pharmaceutical

Teva

Antifibrotic Drug Segment by Type

Nintedanib

Pirfenidone

Antifibrotic Drug Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Antifibrotic Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antifibrotic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antifibrotic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antifibrotic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antifibrotic Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antifibrotic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antifibrotic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antifibrotic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antifibrotic Drug Industry Trends Table 2. Antifibrotic Drug Industry Drivers Table 3. Antifibrotic Drug Industry Opportunities and Challenges Table 4. Antifibrotic Drug Industry Restraints Table 5. Global Antifibrotic Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antifibrotic Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antifibrotic Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Antifibrotic Drug Sales Market Share by Manufacturers Table 9. Global Antifibrotic Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Antifibrotic Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antifibrotic Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antifibrotic Drug Manufacturers, Product Type & Application Table 13. Global Antifibrotic Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antifibrotic Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Nintedanib Table 17. Major Manufacturers of Pirfenidone Table 18. Global Antifibrotic Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Antifibrotic Drug Sales by Type (2021-2026) & (k units) Table 20. Global Antifibrotic Drug Sales by Type (2027-2032) & (k units) Table 21. Global Antifibrotic Drug Sales Market Share by Type (2021-2026) Table 22. Global Antifibrotic Drug Sales Market Share by Type (2027-2032) Table 23. Global Antifibrotic Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Antifibrotic Drug Revenue by Type (2021-2026) & (k units) Table 25. Global Antifibrotic Drug Revenue by Type (2027-2032) & (k units) Table 26. Global Antifibrotic Drug Revenue Market Share by Type (2021-2026) Table 27. Global Antifibrotic Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital and Clinic Table 29. Major Manufacturers of Retail Pharmacies Table 30. Major Manufacturers of Other Table 31. Global Antifibrotic Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Antifibrotic Drug Sales by Application (2021-2026) & (k units) Table 33. Global Antifibrotic Drug Sales by Application (2027-2032) & (k units) Table 34. Global Antifibrotic Drug Sales Market Share by Application (2021-2026) Table 35. Global Antifibrotic Drug Sales Market Share by Application (2027-2032) Table 36. Global Antifibrotic Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Antifibrotic Drug Revenue by Application (2021-2026) & (k units) Table 38. Global Antifibrotic Drug Revenue by Application (2027-2032) & (k units) Table 39. Global Antifibrotic Drug Revenue Market Share by Application (2021-2026) Table 40. Global Antifibrotic Drug Revenue Market Share by Application (2027-2032) Table 41. Global Antifibrotic Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Antifibrotic Drug Sales by Region (2021-2026) & (k units) Table 43. Global Antifibrotic Drug Sales Market Share by Region (2021-2026) Table 44. Global Antifibrotic Drug Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Antifibrotic Drug Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Antifibrotic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 48. North America Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 49. Europe Antifibrotic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 51. Europe Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Antifibrotic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Antifibrotic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 58. Global Antifibrotic Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Antifibrotic Drug Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Antifibrotic Drug Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Antifibrotic Drug Revenue Market Share by Region (2021-2026) Table 62. Global Antifibrotic Drug Revenue Market Share by Region (2027-2032) Table 63. Accord Healthcare Company Information Table 64. Accord Healthcare Business Overview Table 65. Accord Healthcare Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Accord Healthcare Antifibrotic Drug Product Portfolio Table 67. Accord Healthcare Recent Development Table 68. Amneal Pharmaceuticals Company Information Table 69. Amneal Pharmaceuticals Business Overview Table 70. Amneal Pharmaceuticals Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio Table 72. Amneal Pharmaceuticals Recent Development Table 73. Apotex Company Information Table 74. Apotex Business Overview Table 75. Apotex Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Apotex Antifibrotic Drug Product Portfolio Table 77. Apotex Recent Development Table 78. Beacon Pharma Company Information Table 79. Beacon Pharma Business Overview Table 80. Beacon Pharma Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Beacon Pharma Antifibrotic Drug Product Portfolio Table 82. Beacon Pharma Recent Development Table 83. Boehringer Ingelheim Company Information Table 84. Boehringer Ingelheim Business Overview Table 85. Boehringer Ingelheim Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Boehringer Ingelheim Antifibrotic Drug Product Portfolio Table 87. Boehringer Ingelheim Recent Development Table 88. Eskayef Pharmaceuticals Company Information Table 89. Eskayef Pharmaceuticals Business Overview Table 90. Eskayef Pharmaceuticals Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio Table 92. Eskayef Pharmaceuticals Recent Development Table 93. ScieGen Pharmaceuticals Company Information Table 94. ScieGen Pharmaceuticals Business Overview Table 95. ScieGen Pharmaceuticals Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio Table 97. ScieGen Pharmaceuticals Recent Development Table 98. Gyre Pharmaceuticals Company Information Table 99. Gyre Pharmaceuticals Business Overview Table 100. Gyre Pharmaceuticals Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio Table 102. Gyre Pharmaceuticals Recent Development Table 103. Kawin Company Information Table 104. Kawin Business Overview Table 105. Kawin Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Kawin Antifibrotic Drug Product Portfolio Table 107. Kawin Recent Development Table 108. Roche Company Information Table 109. Roche Business Overview Table 110. Roche Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Roche Antifibrotic Drug Product Portfolio Table 112. Roche Recent Development Table 113. Qilu Pharmaceutical Company Information Table 114. Qilu Pharmaceutical Business Overview Table 115. Qilu Pharmaceutical Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Qilu Pharmaceutical Antifibrotic Drug Product Portfolio Table 117. Qilu Pharmaceutical Recent Development Table 118. PuraCap Company Information Table 119. PuraCap Business Overview Table 120. PuraCap Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. PuraCap Antifibrotic Drug Product Portfolio Table 122. PuraCap Recent Development Table 123. Sandoz Company Information Table 124. Sandoz Business Overview Table 125. Sandoz Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Sandoz Antifibrotic Drug Product Portfolio Table 127. Sandoz Recent Development Table 128. CSPC Pharmaceutical Group Company Information Table 129. CSPC Pharmaceutical Group Business Overview Table 130. CSPC Pharmaceutical Group Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio Table 132. CSPC Pharmaceutical Group Recent Development Table 133. Kelun Pharmaceutical Company Information Table 134. Kelun Pharmaceutical Business Overview Table 135. Kelun Pharmaceutical Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Kelun Pharmaceutical Antifibrotic Drug Product Portfolio Table 137. Kelun Pharmaceutical Recent Development Table 138. Teva Company Information Table 139. Teva Business Overview Table 140. Teva Antifibrotic Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Teva Antifibrotic Drug Product Portfolio Table 142. Teva Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Antifibrotic Drug Distributors List Table 146. Antifibrotic Drug Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Antifibrotic Drug Product Image Figure 2. Global Antifibrotic Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antifibrotic Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antifibrotic Drug Sales (2021-2032) & (k units) Figure 5. Global Antifibrotic Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antifibrotic Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Nintedanib Image Figure 9. Pirfenidone Image Figure 10. Global Antifibrotic Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Antifibrotic Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Antifibrotic Drug Sales Market Share by Type (2021-2032) Figure 13. Global Antifibrotic Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Antifibrotic Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Antifibrotic Drug Revenue Market Share by Type (2021-2032) Figure 16. Hospital and Clinic Image Figure 17. Retail Pharmacies Image Figure 18. Other Image Figure 19. Global Antifibrotic Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Antifibrotic Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Antifibrotic Drug Sales Market Share by Application (2021-2032) Figure 22. Global Antifibrotic Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Antifibrotic Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Antifibrotic Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 27. U.S. Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 32. Germany Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 39. China Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 47. Brazil Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Antifibrotic Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Antifibrotic Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Antifibrotic Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Antifibrotic Drug Revenue (2021-2032) & (US$ Million) Figure 58. North America Antifibrotic Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Antifibrotic Drug Revenue (2021-2032) & (US$ Million) Figure 60. Europe Antifibrotic Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Antifibrotic Drug Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Antifibrotic Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Antifibrotic Drug Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Antifibrotic Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Antifibrotic Drug Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Antifibrotic Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Nintedanib
  • Pirfenidone
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Accord Healthcare
  • Amneal Pharmaceuticals
  • Apotex
  • Beacon Pharma
  • Boehringer Ingelheim
  • Eskayef Pharmaceuticals
  • ScieGen Pharmaceuticals
  • Gyre Pharmaceuticals
  • Kawin
  • Roche
  • Qilu Pharmaceutical
  • PuraCap
  • Sandoz
  • CSPC Pharmaceutical Group
  • Kelun Pharmaceutical
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antifibrotic Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antifibrotic Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antifibrotic Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antifibrotic Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antifibrotic Drug Market Dynamics
  1. 2.1 Antifibrotic Drug Industry Trends
  2. 2.2 Antifibrotic Drug Industry Drivers
  3. 2.3 Antifibrotic Drug Industry Opportunities and Challenges
  4. 2.4 Antifibrotic Drug Industry Restraints
3 Antifibrotic Drug Market by Manufacturers
  1. 3.1 Global Antifibrotic Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antifibrotic Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antifibrotic Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antifibrotic Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antifibrotic Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antifibrotic Drug Manufacturers, Product Type & Application
  7. 3.7 Global Antifibrotic Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antifibrotic Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antifibrotic Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antifibrotic Drug Tier 1, Tier 2, and Tier 3
4 Antifibrotic Drug Market by Type
  1. 4.1 Antifibrotic Drug Type Introduction
  2. 4.1.1 Nintedanib
  3. 4.1.2 Pirfenidone
  4. 4.2 Global Antifibrotic Drug Sales by Type
  5. 4.2.1 Global Antifibrotic Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antifibrotic Drug Sales by Type (2021-2032)
  7. 4.2.3 Global Antifibrotic Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global Antifibrotic Drug Revenue by Type
  9. 4.3.1 Global Antifibrotic Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antifibrotic Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global Antifibrotic Drug Revenue Market Share by Type (2021-2032)
5 Antifibrotic Drug Market by Application
  1. 5.1 Antifibrotic Drug Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Antifibrotic Drug Sales by Application
  6. 5.2.1 Global Antifibrotic Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antifibrotic Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Antifibrotic Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Antifibrotic Drug Revenue by Application
  10. 5.3.1 Global Antifibrotic Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antifibrotic Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Antifibrotic Drug Revenue Market Share by Application (2021-2032)
6 Global Antifibrotic Drug Sales by Region
  1. 6.1 Global Antifibrotic Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antifibrotic Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Antifibrotic Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Antifibrotic Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antifibrotic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antifibrotic Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antifibrotic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antifibrotic Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antifibrotic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antifibrotic Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antifibrotic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antifibrotic Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antifibrotic Drug Revenue by Region
  1. 7.1 Global Antifibrotic Drug Revenue by Region
  2. 7.1.1 Global Antifibrotic Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antifibrotic Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Antifibrotic Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Antifibrotic Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antifibrotic Drug Revenue (2021-2032)
  8. 7.2.2 North America Antifibrotic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antifibrotic Drug Revenue (2021-2032)
  11. 7.3.2 Europe Antifibrotic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antifibrotic Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antifibrotic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antifibrotic Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antifibrotic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare
  2. 8.1.1 Accord Healthcare Company Information
  3. 8.1.2 Accord Healthcare Business Overview
  4. 8.1.3 Accord Healthcare Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare Antifibrotic Drug Product Portfolio
  6. 8.1.5 Accord Healthcare Recent Developments
  7. 8.2 Amneal Pharmaceuticals
  8. 8.2.1 Amneal Pharmaceuticals Company Information
  9. 8.2.2 Amneal Pharmaceuticals Business Overview
  10. 8.2.3 Amneal Pharmaceuticals Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio
  12. 8.2.5 Amneal Pharmaceuticals Recent Developments
  13. 8.3 Apotex
  14. 8.3.1 Apotex Company Information
  15. 8.3.2 Apotex Business Overview
  16. 8.3.3 Apotex Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Apotex Antifibrotic Drug Product Portfolio
  18. 8.3.5 Apotex Recent Developments
  19. 8.4 Beacon Pharma
  20. 8.4.1 Beacon Pharma Company Information
  21. 8.4.2 Beacon Pharma Business Overview
  22. 8.4.3 Beacon Pharma Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Beacon Pharma Antifibrotic Drug Product Portfolio
  24. 8.4.5 Beacon Pharma Recent Developments
  25. 8.5 Boehringer Ingelheim
  26. 8.5.1 Boehringer Ingelheim Company Information
  27. 8.5.2 Boehringer Ingelheim Business Overview
  28. 8.5.3 Boehringer Ingelheim Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Boehringer Ingelheim Antifibrotic Drug Product Portfolio
  30. 8.5.5 Boehringer Ingelheim Recent Developments
  31. 8.6 Eskayef Pharmaceuticals
  32. 8.6.1 Eskayef Pharmaceuticals Company Information
  33. 8.6.2 Eskayef Pharmaceuticals Business Overview
  34. 8.6.3 Eskayef Pharmaceuticals Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio
  36. 8.6.5 Eskayef Pharmaceuticals Recent Developments
  37. 8.7 ScieGen Pharmaceuticals
  38. 8.7.1 ScieGen Pharmaceuticals Company Information
  39. 8.7.2 ScieGen Pharmaceuticals Business Overview
  40. 8.7.3 ScieGen Pharmaceuticals Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio
  42. 8.7.5 ScieGen Pharmaceuticals Recent Developments
  43. 8.8 Gyre Pharmaceuticals
  44. 8.8.1 Gyre Pharmaceuticals Company Information
  45. 8.8.2 Gyre Pharmaceuticals Business Overview
  46. 8.8.3 Gyre Pharmaceuticals Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio
  48. 8.8.5 Gyre Pharmaceuticals Recent Developments
  49. 8.9 Kawin
  50. 8.9.1 Kawin Company Information
  51. 8.9.2 Kawin Business Overview
  52. 8.9.3 Kawin Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Kawin Antifibrotic Drug Product Portfolio
  54. 8.9.5 Kawin Recent Developments
  55. 8.10 Roche
  56. 8.10.1 Roche Company Information
  57. 8.10.2 Roche Business Overview
  58. 8.10.3 Roche Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Roche Antifibrotic Drug Product Portfolio
  60. 8.10.5 Roche Recent Developments
  61. 8.11 Qilu Pharmaceutical
  62. 8.11.1 Qilu Pharmaceutical Company Information
  63. 8.11.2 Qilu Pharmaceutical Business Overview
  64. 8.11.3 Qilu Pharmaceutical Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Qilu Pharmaceutical Antifibrotic Drug Product Portfolio
  66. 8.11.5 Qilu Pharmaceutical Recent Developments
  67. 8.12 PuraCap
  68. 8.12.1 PuraCap Company Information
  69. 8.12.2 PuraCap Business Overview
  70. 8.12.3 PuraCap Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 PuraCap Antifibrotic Drug Product Portfolio
  72. 8.12.5 PuraCap Recent Developments
  73. 8.13 Sandoz
  74. 8.13.1 Sandoz Company Information
  75. 8.13.2 Sandoz Business Overview
  76. 8.13.3 Sandoz Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sandoz Antifibrotic Drug Product Portfolio
  78. 8.13.5 Sandoz Recent Developments
  79. 8.14 CSPC Pharmaceutical Group
  80. 8.14.1 CSPC Pharmaceutical Group Company Information
  81. 8.14.2 CSPC Pharmaceutical Group Business Overview
  82. 8.14.3 CSPC Pharmaceutical Group Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio
  84. 8.14.5 CSPC Pharmaceutical Group Recent Developments
  85. 8.15 Kelun Pharmaceutical
  86. 8.15.1 Kelun Pharmaceutical Company Information
  87. 8.15.2 Kelun Pharmaceutical Business Overview
  88. 8.15.3 Kelun Pharmaceutical Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Kelun Pharmaceutical Antifibrotic Drug Product Portfolio
  90. 8.15.5 Kelun Pharmaceutical Recent Developments
  91. 8.16 Teva
  92. 8.16.1 Teva Company Information
  93. 8.16.2 Teva Business Overview
  94. 8.16.3 Teva Antifibrotic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Teva Antifibrotic Drug Product Portfolio
  96. 8.16.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antifibrotic Drug Value Chain Analysis
  2. 9.1.1 Antifibrotic Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antifibrotic Drug Production Mode & Process
  6. 9.2 Antifibrotic Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antifibrotic Drug Distributors
  9. 9.2.3 Antifibrotic Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst